Stocks in play: Marvel Biosciences Corp
Announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures in the principal amount of up to $1,500,000. The Debentures will bear interest at the rate of 8% per annum, payable annually and will mature on the date that is three years from the closing date. Interest may be repaid in cash or Common Shares, at the option of the Company, The Debentures will be convertible at the holder's option into common shares of the Company at a conversion price of $0.12 per Common Share. The closing of the Private Placement is expected to occur on or about February 24, 2023. Marvel Biosciences Corp shares V.MRVL are trading up one cent at $0.11.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
